No Record Found
CALLS | PUTS | |||||||||
Total OI | Chg in Ol | Chg % Ol | LTP | Chg % | Strike Price | Chg % | LTP | Chg % OI | Chg in Ol | Total OI |
No Record Found
sector: Pharmaceuticals
as on 7/3/2024 12:39:56 PM
₹ 437.05 9.90 2.32No Record Found
No Record Found
Resolution Type | Desc. of Resolution | Lias Recommendation |
---|
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
Demat Account
Trading Account
PROMOTER - TOTAL48.19%
Indian: 48.19%
Foreign: 0%
NON-PROMOTER - TOTAL 51.81%
Institutions: 1.71%
Non-Institutions: 50.10%
CUSTODIES - 0.00%
Custodies: 0.00%
Y/e 31 Mar( In .Cr) | Mar-2022 | -- | -- | -- |
---|---|---|---|---|
Revenue | 2184.02 | -- | -- | -- |
yoy growth (%) | -- | -- | -- | -- |
Raw materials | (1,570.51) | -- | -- | -- |
As % of sales | 71.91 | -- | -- | -- |
Employee costs | (141.30) | -- | -- | -- |
As % of sales | 6.47 | -- | -- | -- |
Other costs | (213.92) | -- | -- | -- |
As % of sales | 9.79 | -- | -- | -- |
Operating profit | 258.29 | -- | -- | -- |
OPM | 11.83 | -- | -- | -- |
Depreciation | (43.26) | -- | -- | -- |
Interest expense | (8.29) | -- | -- | -- |
Other income | 32.04 | -- | -- | -- |
Profit before tax | 238.78 | -- | -- | -- |
Taxes | (57.18) | -- | -- | -- |
Tax rate | (23.95) | -- | -- | -- |
Minorities and other | -- | -- | -- | -- |
Adj. profit | 181.60 | -- | -- | -- |
Exceptional items | (13.93) | -- | -- | -- |
Net profit | 167.67 | -- | -- | -- |
yoy growth (%) | -- | -- | -- | -- |
NPM | 7.68 | -- | -- | -- |
Y/e 31 Mar ( In .Cr) | Mar-2023 | Mar-2022 | -- | -- |
---|---|---|---|---|
Equity capital | 58.71 | 58.71 | -- | -- |
Preference capital | -- | -- | -- | -- |
Reserves | 1449.01 | 1333.57 | -- | -- |
Net worth | 1507.72 | 1392.28 | -- | -- |
Minority interest | -- | -- | -- | -- |
Debt | 79.81 | 43.95 | -- | -- |
Deferred tax liabilities (net) | 60.33 | 56.09 | -- | -- |
Total liabilities | 1647.86 | 1492.32 | -- | -- |
Fixed assets | 841.45 | 665.84 | -- | -- |
Intangible assets | -- | -- | -- | -- |
Investments | 19.97 | 2.37 | -- | -- |
Deferred tax asset (net) | 3.97 | 2.91 | -- | -- |
Net working capital | 760.64 | 681.21 | -- | -- |
Inventories | 325.52 | 409.89 | -- | -- |
Inventory Days | -- | 68.50 | -- | -- |
Sundry debtors | 505.28 | 469.80 | -- | -- |
Debtor days | -- | 78.51 | -- | -- |
Other current assets | 308.08 | 274.41 | -- | -- |
Sundry creditors | (330.76) | (415.03) | -- | -- |
Creditor days | -- | 69.36 | -- | -- |
Other current liabilities | (47.48) | (57.86) | -- | -- |
Cash | 21.83 | 139.99 | -- | -- |
Total assets | 1647.86 | 1492.32 | -- | -- |
Y/e 31 Mar ( In .Cr) | Mar-2022 | -- | -- | -- |
---|---|---|---|---|
Profit before tax | 238.78 | -- | -- | -- |
Depreciation | (43.26) | -- | -- | -- |
Tax paid | (57.18) | -- | -- | -- |
Working capital 27,893 | -- | -- | -- | -- |
Other operating items | -- | -- | -- | -- |
Operating cashflow | -- | -- | -- | -- |
Capital expenditure | -- | -- | -- | -- |
Free cash flow | -- | -- | -- | -- |
Equity raised | -- | -- | -- | -- |
Investments | -- | -- | -- | -- |
Debt financing/disposal | -- | -- | -- | -- |
Dividends paid | 35.22 | -- | -- | -- |
Net in cash | -- | -- | -- | -- |
Y/e 31 Mar | Mar-2022 | -- | -- | -- |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | ||||
Op profit growth | ||||
EBIT growth | ||||
Net profit growth | ||||
Profitability ratios (%) | ||||
OPM | 11.826 | |||
EBIT margin | 11.313 | |||
Net profit margin | 7.677 | |||
RoCE | ||||
RoNW | ||||
RoA | ||||
Per share ratios (₹) | ||||
EPS | 28.56 | |||
Dividend per share | 4 | |||
Cash EPS | 21.192 | |||
Book value per share | ||||
Valuation ratios | ||||
P/E | 12.388 | |||
P/CEPS | 16.695 | |||
P/B | 1.492 | |||
EV/EBIDTA | 6.823 | |||
Payout (%) | ||||
Dividend payout | 21.006 | |||
Tax payout | -23.947 | |||
Liquidity ratios | ||||
Debtor days | ||||
Inventory days | ||||
Creditor days | ||||
Leverage ratios | ||||
Interest coverage | -29.803 | |||
Net debt / equity | -0.069 | |||
Net debt / op. profit | -0.372 | |||
Cost breakup (₹) | ||||
Material costs | -71.909 | |||
Employee costs | -6.47 | |||
Other costs | -9.795 |
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Particulars ( Rupees In Crores.) | -- | -- | -- | -- | -- |
---|---|---|---|---|---|
Gross Sales | -- | -- | -- | -- | |
Excise Duty | -- | -- | -- | -- | |
Net Sales | -- | -- | -- | -- | |
Other Operating Income | -- | -- | -- | -- | |
Other Income | -- | -- | -- | -- | |
Total Income | -- | -- | -- | -- | |
Total Expenditure ** | -- | -- | -- | -- | |
PBIDT | -- | -- | -- | -- | |
Interest | -- | -- | -- | -- | |
PBDT | -- | -- | -- | -- | |
Depreciation | -- | -- | -- | -- | |
Minority Interest Before NP | -- | -- | -- | -- | |
Tax | -- | -- | -- | -- | |
Deferred Tax | -- | -- | -- | -- | |
Reported Profit After Tax | -- | -- | -- | -- | |
Minority Interest After NP | -- | -- | -- | -- | |
Net Profit after Minority Interest | -- | -- | -- | -- | |
Extra-ordinary Items | -- | -- | -- | -- | |
Adjusted Profit After Extra-ordinary item | -- | -- | -- | -- | |
EPS (Unit Curr.) | -- | -- | -- | -- | |
Book Value (Unit Curr.) | -- | -- | -- | -- | |
Dividend (%) | -- | -- | -- | -- | |
Equity | -- | -- | -- | -- | |
Public Shareholding (Number) | -- | -- | -- | -- | |
Public Shareholding (%) | -- | -- | -- | -- | |
Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | |
Non Encumbered - No. of Shares | -- | -- | -- | -- | |
Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | |
Non Encumbered - % in Total Equity | -- | -- | -- | -- | |
PBIDTM(%) | -- | -- | -- | -- | |
PBDTM(%) | -- | -- | -- | -- | |
PATM(%) | -- | -- | -- | -- |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd | 1,525.50 | 120.29 | 3,65,682.64 | 867.60 | 0.89 | 5,536.99 | 98.75 |
Divis Laboratories Ltd | 4,560.30 | 76.97 | 1,21,312.50 | 531.00 | 0.66 | 2,259.00 | 507.94 |
Cipla Ltd | 1,484.30 | 32.36 | 1,20,195.02 | 1,038.40 | 0.57 | 3,444.92 | 346.42 |
Zydus Lifesciences Ltd | 1,093.35 | 31.35 | 1,08,114.81 | 1,405.20 | 0.28 | 3,172.60 | 156.19 |
Dr Reddys Laboratories Ltd | 6,496.30 | 24.48 | 1,06,298.05 | 1,034.80 | 0.63 | 5,081.80 | 1,453.03 |
IOL Chemicals and Pharmaceuticals Ltd is a leading organic chemicals manufacturer and supplier in India. The company manufactures active pharmaceutical ingredient, organic chemicals and intermediates. The company was incorporated in the year 1986.The company manufactures and supplies industrial chemicals and bulk drugs for use in various pharmaceutical applications. Their portfolio includes industrial chemicals, industrial organic chemicals and bulk drugs.The company has two segments namely chemicals and pharmaceuticals. Under the chemical division, the company manufactures bulk chemicals, such as acetic acid and specialty chemicals, including ethyl acetate and acetic anhydride. Under pharmaceuticals division, the company manufactures active pharmaceutical ingredient, Ibuprofen.The company has two manufacturing units namely API Unit and Chemical Unit located in Punjab. API Unit manufactures Ibuprofen with the installed Capacity of 10 MTPD. Chemical Unit manufactures organic chemicals such as Glacial Acetic Acid, Ethyl Acetate, Acetic Anhydride, Mono chloro acetic Acid, Acetyl Chloride and Iso butyl Benzene. The company is having their presence in over 40 countries across the world, which includes Bangladesh, Thailand, UAE, Syria, Singapore, Hong Kong, Pakistan, Egypt, and many others. They have strong business relationships with a number of prestigious clients such as Ranbaxy Labs, Dr Reddy. DS Group, Cipla, Uflex Industries, ITC Ltd, ICI Paints, Asian Paints, Pidillte,... Read More
Reports by IOL Chemicals & Pharmaceuticals Ltd
Reports by IOL Chemicals & Pharmaceuticals Ltd
No Record Found
ATTENTION INVESTORS
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Risk Disclosure on Derivatives
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
We are ISO 27001:2013 Certified.
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.